IVORC
  • Register
  • Login

Medical hypothesis discovery and innovation in ophthalmology

  1. Home
  2. Archives
  3. Vol. 9 No. 4 (2020): Winter 2020
  4. Articles

About the Journal

Editorial Team

Privacy Statement

Contact

Preservative-free versus preserved latanoprost eye drops for reducing intraocular pressure: a non-inferiority phase III randomized, multi-center, single-blind, parallel-group controlled trial

  • Panos Theodosiadis
  • Anastasios Konstas
  • Ioannis Halkiadakis
  • Vasiliki Dimera
  • Dimitrios Koufakis
  • Constantinos D Georgakopoulos
  • Evgenia Kanonidou
  • Elias Zintzaras
  • Konstantina Soulele
  • Antonios Margaritis
  • Lida Kalantzi

Medical hypothesis discovery and innovation in ophthalmology, Vol. 9 No. 4 (2020), 28 February 2021 , Page 273-283
https://doi.org/10.51329/mehdiophthal1413 Published 28 February 2021

  • View Article
  • Download
  • Share

Abstract

Background: The aim of this study was to test the non-inferiority of preservative-free (PF) latanoprost 50 micrograms per milliliter multi-dose ophthalmic solution versus the marketed benzalkonium chloride (BAK)-preserved latanoprost 50 micrograms per milliliter ophthalmic solution in patients with open-angle glaucoma and patients with ocular hypertension.
Methods: This was a prospective, national, randomized, multi-center, observer-blind, parallel-group controlled clinical trial. Patients were randomized to receive either PF or BAK-preserved latanoprost once daily for 12 weeks. The primary endpoint was the change in intraocular pressure (IOP) at 8:00 AM in the affected eye between the end of the treatment (week 12) and the baseline (week 0). Secondary measurements were taken at weeks 2 and 6, with IOP being recorded at 8:00 AM, 12:00 PM, and 4:00 PM.
Results: A total of 158 patients were included in the per protocol (PP) population (77 in the PF latanoprost treatment arm and 81 patients in the BAK-preserved latanoprost treatment arm). PF latanoprost was non-inferior to BAK-preserved latanoprost in reducing IOP at 8:00 AM in the study eye from the baseline (week 0) to the end of the treatment (week 12). The point estimate of the between-treatment difference was 0.1 mmHg (95% confidence interval: -0.646, 0.847). Mean between-group differences in IOP reduction from the baseline to each of the secondary measurements were also similar between the two treatment arms. The two treatments were well tolerated and had comparable adverse event profiles.
Conclusions: PF latanoprost was non-inferior to BAK-preserved latanoprost in reducing IOP in patients with open-angle glaucoma or ocular hypertension. Both treatments were well tolerated.
  • Full Text PDF
  • Abstract Viewed: 295 times
  • Full Text PDF Downloaded: 199 times

Download Statastics

  • Linkedin
  • Twitter
  • Facebook
  • Google Plus
  • Telegram
Open Journal Systems
Current Issue
  • Atom logo
  • RSS2 logo
  • RSS1 logo
Information
  • For Readers
  • For Authors
  • For Librarians
  • Home
  • Archives
  • Submissions
  • About the Journal
  • Editorial Team
  • Contact

ISSN: 2322-3219

This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).
© Copyright 2012-2023, CC BY-NC 4.0. All Rights Reserved.